It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Sinus node (SN) pacemaking is based on a coupling between surface membrane ion-channels and intracellular Ca2+-handling. The fundamental role of the inward Na+/Ca2+ exchanger (NCX) is firmly established. However, little is known about the reverse mode exchange. A simulation study attributed important role to reverse NCX activity, however experimental evidence is still missing. Whole-cell and perforated patch-clamp experiments were performed on rabbit SN cells supplemented with fluorescent Ca2+-tracking. We established 2 and 8 mM pipette NaCl groups to suppress and enable reverse NCX. NCX was assessed by specific block with 1 μM ORM-10962. Mechanistic simulations were performed by Maltsev–Lakatta minimal computational SN model. Active reverse NCX resulted in larger Ca2+-transient amplitude with larger SR Ca2+-content. Spontaneous action potential (AP) frequency increased with 8 mM NaCl. When reverse NCX was facilitated by 1 μM strophantin the Ca2+i and spontaneous rate increased. ORM-10962 applied prior to strophantin prevented Ca2+i and AP cycle change. Computational simulations indicated gradually increasing reverse NCX current, Ca2+i and heart rate with increasing Na+i. Our results provide further evidence for the role of reverse NCX in SN pacemaking. The reverse NCX activity may provide additional Ca2+-influx that could increase SR Ca2+-content, which consequently leads to enhanced pacemaking activity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Szeged, Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625)
2 Karlsruhe Institute of Technology (KIT), Institute of Biomedical Engineering, Karlsruhe, Germany (GRID:grid.7892.4) (ISNI:0000 0001 0075 5874)
3 ELKH-SZTE Research Group of Cardiovascular Pharmacology, Szeged, Hungary (GRID:grid.9008.1)
4 Orion Pharma, Espoo, Finland (GRID:grid.419951.1) (ISNI:0000 0004 0400 1289)
5 University of Szeged, Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625); ELKH-SZTE Research Group of Cardiovascular Pharmacology, Szeged, Hungary (GRID:grid.9008.1)